ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Adalimumab and juvenile arthritis"

  • Abstract Number: 1678 • 2012 ACR/ARHP Annual Meeting

    Safety and Efficacy of Adalimumab in Children with Active Polyarticular Juvenile Idiopathic Arthritis Aged 2 to <4 Years or ≥4 Years Weighing <15 Kg

    Daniel J. Kingsbury1, Pierre Quartier2, Gina Patel3, Vipin Arora4, Hartmut Kupper5 and Neelufar Mozaffarian3, 1Randall Children's Hospital at Legacy Emanuel, Portland, OR, 2Unite d'Immuno-Hematologie et Rhumatologie Pediatriques, Paris, France, 3Abbott, Abbott Park, IL, 4Health Outcomes Research, Abbott, Abbott Park, IL, 5Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany

    Background/Purpose: Adalimumab (ADA) is approved for use in moderate to severe JIA in patients (pts) ≥4 yrs old in the US, EU,and Japan. ADA has…
  • Abstract Number: 1148 • 2012 ACR/ARHP Annual Meeting

    Adalimumab – Effective Control under Refractory JIA Associated Uveitis

    Ekaterina Alekseeva1, Elena Mitenko2, Tatyana Bzarova2, Saniya Valieva2, Kseniya Isayeva2, Alexandra Chomakhidze2, Evgeniya Chistyakova2, Tatyana Sleptsova2 and Rina Denisova2, 1PRINTO, Genoa, Italy, 2Rheumatology, Scientific Center of Children's Health, Moscow, Russia

    Background/Purpose: Treatment of juvenile idiopathic arthritis (JIA)–associated uveitis  is one of the serious problems of paediatric rheumatology. JIA associated uveitis often is refractory to MTX,…
  • Abstract Number: 764 • 2012 ACR/ARHP Annual Meeting

    The Impact of Adalimumab On Growth in Patients with Juvenile Idiopathic Arthritis

    D. J. Lovell1, Nicolino Ruperto2, Katerina Jarosova3, Dana Nemcova4, Veronika Vargova3, Hartmut Michels3, Elizabeth Chalom5, Norman Ilowite5, Carine Wouters6, Hermine Brunner7, Karolyn Kracht8, Hartmut Kupper9, Edward Giannini5, Alberto Martini10 and Neelufar Mozaffarian11, 1Cincinnati Children's Hospital, Cincinnati, OH, 2Paediatric Rheumatology International Trials Organisation–IRCCS [PRINTO], Genova, Italy, 3PRINTO, Gaslini Institute, Genova, Italy, 4Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, 5PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 6PRINTO, Genoa, Italy, 7PRCSG, Cincinnati Children’s Hospital Medical Center, Genova, Italy, 8Abbott, Abbott, Abbott Park, IL, 9Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, 10Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, 11Abbott, Abbott Park, IL

     Background/Purpose: Children with juvenile idiopathic arthritis (JIA) often exhibit growth impairments. Treatment with adalimumab (ADA) has been shown to be safe and effective in JIA…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology